Key Players and Competitive Dynamics in the Yellow Fever Vaccine Market

The yellow fever vaccine market is poised for steady expansion over the coming years, driven by various global health dynamics and advancements in vaccine strategies. This analysis will explore the market's projected size, key players, current trends, and the main segments that define the industry's structure and growth potential.

Forecasted Market Size and Growth Trends in the Yellow Fever Vaccine Market
By 2030, the yellow fever vaccine market is anticipated to reach a value of $5.88 billion, growing at a compound annual growth rate (CAGR) of 4.3%. Several factors are propelling this growth, including the increased spread of mosquitoes due to climate change, rising global travel, the expansion of vaccination infrastructure, greater funding dedicated to disease prevention, and enhanced readiness for outbreaks. Key trends shaping the market outlook include the broadening of routine immunization programs, surging demand from international travelers, intensified government-led vaccination efforts, growing preference for single-dose vaccines, and a strategic focus on preventing endemic yellow fever outbreaks.

Download a free sample of the yellow fever vaccine market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17297&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Players Steering the Yellow Fever Vaccine Market
The yellow fever vaccine market features several prominent companies that play critical roles in vaccine development and distribution. Notable organizations in this space include Sanofi S.A., Bio-Manguinhos, Institut Pasteur de Dakar, Instituto Butantan, Bio Farma, Biological E. Limited, Beijing Tiantan Biological Products Co. Ltd., Wuhan Institute of Biological Products, Merck & Co. Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Lonza Group AG, WuXi Biologics, Ology Bioservices, Valneva SE, Bavarian Nordic A/S, Panacea Biotec Ltd., Biovac, Novavax Inc., and PnuVax Incorporated.

Innovative Collaborations and Advances in Yellow Fever Treatment
In a significant development in November 2025, Mabloc, LLC, a US-based biotech firm, partnered with Brazil's Instituto Butantan to develop a pioneering monoclonal antibody therapy aimed at treating and preventing yellow fever. This collaboration focuses on creating a safe and effective post-exposure and preventive treatment to meet the unmet medical need for disease-specific solutions. Instituto Butantan is recognized as a leading public research institution and vaccine manufacturer based in Brazil.

View the full yellow fever vaccine market report:
https://www.thebusinessresearchcompany.com/report/yellow-fever-vaccine-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Highlighted in the Yellow Fever Vaccine Market
Leading companies in this market are increasingly investing in new technologies, such as T-cell adaptive booster vaccines, which are designed to boost long-term immunity by enhancing T-cell responses. This approach aims to improve vaccine effectiveness and overcome limitations associated with traditional live-attenuated vaccines, which mainly stimulate antibody responses. For example, in April 2025, the All India Institute of Medical Sciences launched a Yellow Fever Vaccination program that offers travelers protection against the disease and provides internationally accepted vaccination certificates. This initiative improves vaccine accessibility in Telangana by reducing the need for travel to distant vaccination centers and ensures safe administration under medical supervision, especially for individuals with contraindications. It also helps maintain compliance with international health regulations.

Segment Overview of the Global Yellow Fever Vaccine Market
The report categorizes the yellow fever vaccine market across several principal segments:
1) By Product Type: Powder and Liquid
2) By Application: Routine Immunization, Travelers, and Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Point of Care Centers, and Other End Users

Further sub-segmentation includes:
- Powder vaccines divided into Lyophilized Powder for Reconstitution and Freeze-Dried Powder for Reconstitution
- Liquid vaccines segmented into Ready-to-Use Liquid Vaccine and Liquid Vaccine in Pre-Filled Syringes

This detailed segmentation provides a comprehensive framework to understand the various dimensions of the yellow fever vaccine market and guide strategic decisions for stakeholders.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.